Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Treating BRCA breast cancer with PARP inhibition

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 1679

Dr Mika Sovak - AstraZeneca, Cambridge, UK

Dr Sovak speaks with ecancer at ASCO 2017 about the findings presented at an earlier press conference, in which olaparib showed effectiveness in treating breast cancer patients whose tumours contained BRCA mutations.

She describes the mechanism of actions of targeting DNA repair, and considers the wider application of PARP inhibitors across ovarian and prostate cancer.

For more on the OlympiAD trial, ecancer spoke with Dr Mark Robson, here.


Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation